Provided by Tiger Trade Technology Pte. Ltd.

AKESO

93.600
-1.450-1.53%
Volume:7.15M
Turnover:672.65M
Market Cap:86.21B
PE:-65.01
High:96.000
Open:95.050
Low:93.400
Close:95.050
52wk High:156.000
52wk Low:80.200
Shares:921.00M
HK Float Shares:921.00M
Volume Ratio:0.46
T/O Rate:0.78%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.440
ROE:-13.59%
ROA:-4.57%
PB:8.70
PE(LYR):-65.01
PS:21.39

Loading ...

Movement Alert|AKESO Declines 3.41% in Regular Trading, Profit-Taking Resumes After Prior Sessions Sharp Rebound

Market Focus
·
Aug 21

Earning Preview: AKESO revenue is expected to increase, institutional views lean positive

Earnings Agent
·
Aug 20

Movement Alert|AKESO Rises 6.49% in Regular Trading, Earnings Preview and Technical Rebound After Overselling Drive Recovery

Market Focus
·
Aug 20

Akeso (SEHK:9926) Could Be 47% Undervalued As China Approves Ivonescimab Use

Simply Wall St.
·
Aug 19

Movement Alert|AKESO Falls 3.09% in Regular Trading, Profit-Taking Continues After Third Indication Approval

Market Focus
·
Aug 18

Movement Alert|AKESO Falls 3.49% in Regular Trading, Profit-Taking Continues After Third Indication Approval for Ivonescimab

Market Focus
·
Aug 17

What Does Akeso (SEHK:9926) China Lung Cancer Approval Mean For Investors?

Simply Wall St.
·
Aug 14

Movement Alert|AKESO Falls 3.19% in Regular Trading, Biotech Sector Broadly Under Pressure After Third Indication Approval

Market Focus
·
Aug 14

Akeso's Ivonescimab Gets Third Indication Approval in China

MT Newswires Live
·
Aug 13

Movement Alert|AKESO Rises 3.04% in Regular Trading, Third Indication of Bispecific Antibody Ivonescimab Approved by NMPA

Market Focus
·
Aug 13

Akeso Says NMPA Approves Ivonescimab for 1L Treatment of SQ-NSCLC

Reuters
·
Aug 13

Summit Gains After Partner Akeso Secures China Nod for Lung Cancer Combo

Reuters
·
Aug 12

AKESO (09926) Gains NMPA Nod for Third Indication of Its First-in-Class Bispecific Antibody, Ivonescimab, in Frontline Squamous NSCLC

Stock News
·
Aug 12

Akeso - Nmpa Approves Ivonescimab for 1L Treatment of Sq-Nsclc

THOMSON REUTERS
·
Aug 12

Akeso Says China NMPA Approves Ivonescimab Plus Chemo for First-Line Squamous NSCLC

Reuters
·
Aug 12

Akeso - China Nmpa Approves Ivonescimab Plus Chemotherapy for First-Line Advanced Squamous Nsclc

THOMSON REUTERS
·
Aug 12

Akeso (SEHK:9926) Could Be 41% Undervalued On Phase II Breast Cancer Trial Progress

Simply Wall St.
·
Aug 11

HK Movers | Hong Kong Biotech Stocks Rally; Genscript Bio Jumps Over 7%, Zai Lab Gains Over 6%

Tiger Newspress
·
Aug 11

Movement Alert|AKESO Rises 3.15% in Regular Trading, Bispecific ADC Plus Ivonescimab Completes First Patient Dosing in Breast Cancer Phase II Trial

Market Focus
·
Aug 11

Akeso Doses First Patient in Phase II Trial of Ak146d1 ADC Plus Ivonescimab in Advanced Breast Cancer

Reuters
·
Aug 10